Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 118.00 | |
5 mg | In stock | $ 278.00 | |
10 mg | In stock | $ 408.00 | |
25 mg | In stock | $ 658.00 | |
50 mg | In stock | $ 900.00 | |
100 mg | In stock | $ 1,350.00 | |
500 mg | In stock | Inquiry |
Description | GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury. |
Targets&IC50 | nNOS (rat):252 μM(ED50), iNOS (human):2.19 μM(kd), eNOS (human):544 μM(kd), iNOS:(kd)40 nM, iNOS (rat): 1.15 μM(ED50), nNOS (human):177 μM(kd), iNOS:40 nM(kd), iNOS (rat):1.15 μM(ED50) |
In vitro |
GW274150 inhibits intracellular iNOS in J774 cells in a time-dependent manner with an IC50 value of 0.2 μM.[1] GW274150 is >260-fold and 219-fold selective for eNOS and nNOS, respectively, in rat tissue. Shows >100-fold and >80-fold selectivity for human eNOS and nNOS, respectively.[1] |
In vivo |
GW274150 is a long-acting (half-life in rats is 5 hours) iNOS inhibitor, which can inhibit the LPS-mediated increase in plasma NO2- and NO3- levels 14 h after a single intraperitoneal administration (ED50=3 mg/kg ).[2] GW274150 (2.5, 5, and 10 mg/kg; i.p.; before carrageenan injection; SD rats) reduces the extent of carrageenan-induced lung injury in a dose-related manner. Pleural cavity edema formation and PMN infiltration were also significantly attenuated in a dose-related manner in rats.[2] GW274150 (30 mg/kg; oral; twice daily; 7 days; SD rats) resulted in significant neuroprotection, however, it showed bell-shaped neuroprotection in 6-OHDA rats with Parkinson's disease (PD) Ineffective at high doses in the model.[3] |
Molecular Weight | 219.3 |
Formula | C8H17N3O2S |
CAS No. | 210354-22-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1 mg/mL (insoluble or slightly soluble)
H2O: 50 mg/mL (228 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GW274150 210354-22-6 Immunology/Inflammation NOS GW 274150 GW-274150 inhibitor inhibit